- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00290706
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
A Phase I/II Trial of Combination Bortezomib (VELCADE) and Gemcitabine Therapy for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with bortezomib may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when given together with gemcitabine and to see how well they work in treating patients with relapsed or refractory B-cell or T-cell non-Hodgkin's lymphoma.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
Primary
- Determine the response rate (complete and partial remission) in patients with relapsed or refractory aggressive B- or T-cell non-Hodgkin's lymphoma treated with gemcitabine hydrochloride and bortezomib.
- Determine the maximum tolerated dose of bortezomib when administered with gemcitabine hydrochloride in these patients.
Secondary
- Determine the time to treatment failure, duration of response, and overall survival of patients treated with this regimen.
- Determine the safety and tolerability of this regimen in these patients.
OUTLINE: This is a phase I, dose-escalation study of bortezomib followed by a phase II, open-label study.
- Phase I: Patients receive gemcitabine hydrochloride IV over 30 minutes and bortezomib IV over 3-5 seconds on days 1 and 8. Treatment repeats every 21 days for up to 9 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity (DLT) OR the dose that at which 2 of 6 patients experience DLT.
- Phase II: Patients receive gemcitabine hydrochloride and bortezomib as in phase I at the MTD.
After completion of study therapy, patients are followed periodically for 3 years.
PROJECTED ACCRUAL: A total of 37 patients will be accrued for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern University
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago Cancer Research Center
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Veterans Affairs Medical Center - Lakeside Chicago
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Diagnosis of B- or T-cell non-Hodgkin's lymphoma (NHL)
Intermediate histology B-cell NHL, including any of the following:
- Diffuse large B-cell lymphoma
- Transformed large cell lymphoma
- Any T-cell NHL histology
- Cutaneous T-cell lymphoma (CTCL) or mycosis fungoides (MF) allowed
- Relapsed or refractory disease, defined as disease progressed after prior complete remission (CR), partial remission (PR), or stable disease (SD) to last therapy OR failure to achieve CR, PR, or SD after completion of last therapy
Must have received 1-3 prior therapeutic regimens
- Cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) AND cyclophosphamide, vincristine, and prednisone (CVP) OR CHOP with rituximab (CHOP-R) AND CVP with rituximab (CVP-R) is considered 1 regimen
- Monoclonal antibody (e.g., rituximab) given as maintenance therapy is considered 1 regimen
- Salvage chemotherapy followed by an autologous stem cell transplant is considered 1 regimen
- No more than 7 prior therapeutic regimens for patients with CTCL or MF
- No mantle cell lymphoma
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy > 3 months
- Absolute neutrophil count ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
- At least 50,000/mm^3 if documented bone marrow involvement
- Hemoglobin ≥ 8.0 g/dL
- AST and ALT ≤ 3 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 3 times ULN
- Bilirubin ≤ 2 times ULN
- Creatinine ≤ 2.0 mg/dL
- No known history of HIV infection
- No other active infection
- No uncontrolled hypertension
- No peripheral neuropathy ≥ grade 2 within the past 2 weeks
- No myocardial infarction within the past 6 months
- No New York Heart Association class III or IV heart failure
- No uncontrolled angina
- No severe uncontrolled ventricular arrhythmias
- No acute ischemia or active conduction system abnormalities by ECG
- No hypersensitivity to bortezomib, boron, or mannitol
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier-method contraception
- No serious medical or psychiatric illness that would preclude study participation
PRIOR CONCURRENT THERAPY:
- Prior autologous and/or allogeneic stem cell transplantation allowed
- More than 3 weeks since prior chemotherapy, radiotherapy, or immunotherapy
- More than 3 weeks since prior systemic biologic anticancer therapy
- More than 3 weeks since prior systemic corticosteroids (e.g., oral prednisone > 10 mg per day)
- More than 2 weeks since prior investigational drug
- No prior bortezomib or gemcitabine hydrochloride
- No other concurrent systemic cytotoxic chemotherapy or investigational agents
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Gemcitabine 800 mg/m2 + Bortezomib IVP over 3-5 seconds
Gemcitabine dose of 800 mg/m2 over 30 minutes followed by Bortezomib IVP given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
|
Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
Andere Namen:
Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Response Rate in Patients With Relapsed or Refractory B- and T-cell NHL With Gemcitabine and Bortezomib Combination Treatment.
Zeitfenster: At screening and after completing cycle 3, cycle 6 and 30 days after Cycle 8
|
Response rate in patients with relapsed or refractory B- and T-cell NHL with Gemcitabine and Bortezomib combination treatment will be defined as the number of patients with Complete Remission [CR] and Partial Remission [PR]. CT scans at screening and after completing cycle 3, cycle 6 and 30 days after Cycle 8 assessed by the Response Criteria for Non-hodgkins Lymphoma will be used to determine response where: CR=Complete disappearance of all detectable clinical and radiographic evidence of disease PR=> 50% decrease in SPD of the six largest dominant nodes or nodal masses |
At screening and after completing cycle 3, cycle 6 and 30 days after Cycle 8
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Time to Treatment Failure and Duration of Response
Zeitfenster: At screening and after completing cycle 3, cycle 6 and 30 days after cycle 8, then every 6 months for 3 years
|
Time to treatment failure and duration of response will be measured by CT Scan at screening and after completing cycle 3, cycle 6 and 30 days after cycle 8, then every 6 months for 3 years
|
At screening and after completing cycle 3, cycle 6 and 30 days after cycle 8, then every 6 months for 3 years
|
Overall Survival
Zeitfenster: Every 6 months while on treatment and then every 6 months while off of treatment for up to 3 years
|
Overall survival will be evaluated every 6 months while on treatment and then every 6 months while off of treatment for up to 3 years
|
Every 6 months while on treatment and then every 6 months while off of treatment for up to 3 years
|
Evaluate Safety and Tolerability of Bortezomib and Gemcitabine Therapy
Zeitfenster: During treatment through a maximum of 8 Cycles (1 Cycle = 28 Days) and 30 days post last treatment
|
Safety and tolerability of the study drugs will be assessed on Day 1 and on either Day 8 or Day 15 of each treatment cycle (1 Cycle - 28 days) while on active treatment; and 30 days post last treatment. Adverse Events that are experienced by patients, determined to be either grade 3 or grade 4 and at least possibly related to at least one of the study drugs as assessed according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0) will be collected. In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE |
During treatment through a maximum of 8 Cycles (1 Cycle = 28 Days) and 30 days post last treatment
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Leo Gordon, MD, Northwestern University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- rezidivierendes follikuläres Lymphom Grad 3
- rezidivierendes diffuses großzelliges Lymphom bei Erwachsenen
- rezidivierendes erwachsenes immunblastisches großzelliges Lymphom
- rezidivierendes diffuses gemischtzelliges Lymphom bei Erwachsenen
- rezidivierendes lymphoblastisches Lymphom bei Erwachsenen
- rezidivierendes kutanes T-Zell-Non-Hodgkin-Lymphom
- rezidivierende Mycosis fungoides/Sezary-Syndrom
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Lymphoproliferative Erkrankungen
- Lymphatische Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom
- Lymphom, Non-Hodgkin
- Lymphom, T-Zell
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Gemcitabin
- Bortezomib
Andere Studien-ID-Nummern
- NU 04H4 (Andere Kennung: Northwestern University)
- VEL-03-082
- STU00007425 (Andere Kennung: Northwestern University IRB)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lymphom
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.RekrutierungDiffuses großzelliges B-Zell-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Primäres mediastinales (thymisches) großes B-Zell-Lymphom | Follikuläres Lymphom Grad 3b | Transformierte follikuläre Lymphe zu Diff Large B-Zell-Lymphom und andere BedingungenVereinigte Staaten
Klinische Studien zur bortezomib
-
The First Affiliated Hospital of Soochow UniversityUnbekanntMultiples Myelom durch Labortests nachgewiesenChina
-
Zhongnan HospitalRekrutierungAkute myeloische Leukämie | BortezomibChina
-
Weill Medical College of Cornell UniversityGlaxoSmithKline; Millennium Pharmaceuticals, Inc.AbgeschlossenNon-Hodgkin-LymphomVereinigte Staaten
-
International Extranodal Lymphoma Study Group (IELSG)BeendetLymphom, Schleimhaut-assoziiertes lymphatisches GewebeSchweiz
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Millennium Pharmaceuticals, Inc.AbgeschlossenKopf-Hals-Krebs | Neubildungen des zentralen Nervensystems | Hirntumor | GebärmutterhalskrebsVereinigte Staaten
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; Millennium...AbgeschlossenLymphoplasmatisches Lymphom | Waldenströms MakroglobulinämieVereinigte Staaten
-
OncotherapeuticsMillennium Pharmaceuticals, Inc.BeendetMultiples MyelomVereinigte Staaten
-
Janssen-Cilag International NVAbgeschlossen
-
AHS Cancer Control AlbertaTom Baker Cancer CentreRekrutierung
-
University of ArkansasMillennium Pharmaceuticals, Inc.BeendetMultiples MyelomVereinigte Staaten